Haemoglobin iron is oxidised all the time. Ferrous haem sits in high oxygen and slowly gives up an electron, and the red cell reduces it back so efficiently that almost none of the oxidised form is ever present. Drug-induced methemoglobinemia is that balance losing on the production side. An oxidant drug or chemical raises the rate of formation past what an intact reductase can recover, and ferric haem accumulates. Ferric haem does not carry oxygen, so carrying capacity falls in proportion to the fraction converted. The entry is curated as a phenocopy. Hereditary methemoglobinemia reaches the same accumulated ferric haem by losing the reductase, and this disease reaches it by outrunning one that works. The measurement at the bedside is identical: cyanosis that oxygen does not fix, a pulse oximeter that cannot be trusted, and a normal arterial oxygen tension beside it. What separates them is the exposure and the fact that this one ends when the exposure does.
Ask a research question about Drug-Induced Methemoglobinemia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Drug-Induced Methemoglobinemia:
name: Drug-Induced Methemoglobinemia
creation_date: '2026-09-02T18:00:00Z'
description: >-
Haemoglobin iron is oxidised all the time. Ferrous haem sits in high oxygen and
slowly gives up an electron, and the red cell reduces it back so efficiently
that almost none of the oxidised form is ever present. Drug-induced
methemoglobinemia is that balance losing on the production side. An oxidant
drug or chemical raises the rate of formation past what an intact reductase can
recover, and ferric haem accumulates. Ferric haem does not carry oxygen, so
carrying capacity falls in proportion to the fraction converted.
The entry is curated as a phenocopy. Hereditary methemoglobinemia reaches the
same accumulated ferric haem by losing the reductase, and this disease reaches
it by outrunning one that works. The measurement at the bedside is identical:
cyanosis that oxygen does not fix, a pulse oximeter that cannot be trusted, and
a normal arterial oxygen tension beside it. What separates them is the exposure
and the fact that this one ends when the exposure does.
categories:
- Toxic Exposure Disorder
- Treatment Toxicity
category: Complex
parents:
- Poisoning
disease_term:
preferred_term: drug-induced methemoglobinemia
term:
id: MONDO:0018740
label: drug-induced methemoglobinemia
pathophysiology:
- name: Baseline Haemoglobin Autoxidation
description: >-
The standing condition this disease perturbs, curated as a node because
without it the disease looks like the appearance of something abnormal rather
than the failure of an existing balance. Ferrous haem is continuously oxidised
simply by sitting in oxygen.
role: trigger
biological_scale: MOLECULAR
evidence:
- reference: PMID:8416301
reference_title: "Concise review: methemoglobinemia."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The ferrous iron of hemoglobin is exposed continuously to high
concentrations of oxygen and, thereby, is oxidized slowly to methemoglobin,
a protein unable to carry oxygen.
explanation: >-
Establishes that the oxidation is continuous and physiological, and that the
product cannot carry oxygen.
downstream:
- target: Methemoglobin Accumulation
causal_link_type: DIRECT
description: >-
Baseline oxidation feeds the pool that the reductase drains. On its own it
never accumulates, which is what the next node explains.
- name: NADH-Cytochrome b5 Reductase Recovery Capacity
description: >-
The draining side of the balance, and the reason baseline oxidation is
invisible. Red cell NADH-cytochrome b5 reductase reduces ferric haem back so
efficiently that circulating methemoglobin is insignificant. In this disease
the enzyme is intact and simply outpaced. In the hereditary disease it is
deficient. That is the whole difference between the two.
role: modifier
biological_scale: MOLECULAR
molecular_functions:
- preferred_term: NADH-cytochrome b5 reductase activity
term:
id: GO:0004128
label: cytochrome-b5 reductase activity, acting on NAD(P)H
evidence:
- reference: PMID:8416301
reference_title: "Concise review: methemoglobinemia."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Under physiological conditions, methemoglobin reduction is accomplished
mainly by red cell NADH-cytochrome b5 reductase (NADH-methemoglobin
reductase) so efficiently that there is insignificant amounts of
methemoglobin in the circulating blood.
explanation: >-
Names the enzyme and states that its efficiency is why the baseline pool
stays negligible.
- reference: PMID:8416301
reference_title: "Concise review: methemoglobinemia."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
However, should methemoglobin formation be increased--e.g., due to the
presence of oxidant drugs, or an abnormal methemoglobin not amenable to
reduction (hemoglobin M), or a deficiency in red cell cytochrome b5
reductase--methemoglobinemia will result.
explanation: >-
The phenocopy sentence. It names increased formation by oxidant drugs and
reductase deficiency as alternative routes to the same endpoint, which is
the structure this entry and Hereditary_Methemoglobinemia share.
downstream:
- target: Methemoglobin Accumulation
causal_link_type: DIRECT
description: >-
Recovery capacity sets the level at which formation becomes accumulation.
The edge is drawn from the capacity node because in this disease the
capacity is what is exceeded, not what is lost.
- name: Systemic Oxidant Exposure
description: >-
The oxidant present in the circulation, before anything has happened to haem.
Separated from the oxidation it causes because the compounds divide here into
two kinds: those that oxidise haem as they are, and those that must be
converted to something else first.
role: trigger
biological_scale: ORGANISM
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Aromatic compounds are responsible for most cases, their lipophilic nature
and volatility facilitating absorption during dermal and inhalational
exposure, the principal routes implicated in the workplace.
explanation: >-
Names the dominant chemical class and how it is absorbed, which is what this
node holds before any oxidation occurs.
downstream:
- target: Direct Oxidation of Ferrous Haem
causal_link_type: DIRECT
description: >-
Compounds that oxidise haem directly act from here.
- target: Co-Oxidation of Ferrous Haem
causal_link_type: DIRECT
description: >-
Compounds acting by co-oxidation, such as nitrites, act from here.
- target: Biotransformation to an Oxidising Intermediate
causal_link_type: DIRECT
description: >-
Compounds that are not themselves the oxidant enter this route instead. The
parent chemical is a protoxin.
- target: Hemolytic anemia
causal_link_type: DIRECT
description: >-
The oxidant damages the red cell as well as its haem, and this edge is drawn
from the exposure rather than from the accumulated methemoglobin on purpose.
The cited source states that not every feature belongs to the methemoglobin,
and names chlorates as a case where the haemolysis is the greater threat to
life. Modelling the haemolysis as downstream of the methemoglobin would
assert a causal claim the source contradicts.
- name: Biotransformation to an Oxidising Intermediate
description: >-
Conversion of a chemical to an active intermediate that then initiates
methemoglobin formation. This is a distinct step and not a manner of
oxidising: the parent compound is inert toward haem and the metabolism is
what makes it dangerous. It is how most aromatic amino and nitro compounds
act, which is the group responsible for most occupational cases.
role: intermediate
biological_scale: MOLECULAR
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Thirdly, biotransformation of a chemical to an active intermediate that
initiates methaemoglobin formation by a variety of mechanisms.
explanation: >-
States the conversion step and that what follows it varies, which is why
this node ends at the intermediate rather than naming a single downstream
chemistry.
downstream:
- target: Direct Oxidation of Ferrous Haem
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
description: >-
The intermediate then oxidises haem. The source says it does so by a variety
of mechanisms and does not say which, so this edge is drawn to the direct
route without asserting that the intermediate acts only that way.
- name: Direct Oxidation of Ferrous Haem
description: >-
Electrons pass straight from ferrous haem to the oxidising compound, with no
intermediary and no requirement for bound oxygen. The source notes it
proceeds most readily in the absence of oxygen, which is the property that
separates it from co-oxidation and the reason the two are curated apart.
role: central_effector
biological_scale: MOLECULAR
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Firstly, direct oxidation of ferrohaemoglobin, which involves the transfer
of electrons from ferrous haem to the oxidising compound.
explanation: >-
Names the route and the electron transfer that defines it.
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
This mechanism proceeds most readily in the absence of oxygen.
explanation: >-
Gives the oxygen dependence, which is what distinguishes this node from
co-oxidation rather than merely describing it.
downstream:
- target: Methemoglobin Accumulation
causal_link_type: DIRECT
description: >-
Formation exceeding recovery is what accumulation means here.
- name: Co-Oxidation of Ferrous Haem
description: >-
Oxidation that requires haemoglobin-bound oxygen, so it needs the very thing
direct oxidation does better without. This is how nitrites act, and it is the
reason the two routes are separate nodes rather than one: their oxygen
requirements are opposite.
role: central_effector
biological_scale: MOLECULAR
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Secondly, indirect oxidation, a process of co-oxidation which requires
haemoglobin-bound oxygen and is involved, for example, in nitrite-induced
methaemoglobinaemia.
explanation: >-
Gives the oxygen requirement and the nitrite example, both of which this
node is built on.
downstream:
- target: Methemoglobin Accumulation
causal_link_type: DIRECT
description: >-
Formation exceeding recovery is what accumulation means here.
- name: Methemoglobin Accumulation
description: >-
Ferric haem present at a level that matters. This is the node the hereditary
disease and this one share, and everything below it is common to both. Most
accumulation is not clinically important; concentrations around 80 percent are
life-threatening.
role: central_effector
biological_scale: ORGANISM
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Methaemoglobinaemia presents clinically with symptoms and signs of tissue
hypoxia. Concentrations around 80% are life-threatening.
explanation: >-
Gives the clinical consequence and the concentration at which it becomes
lethal.
- reference: PMID:8416301
reference_title: "Concise review: methemoglobinemia."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Most methemoglobinemias have no adverse clinical consequences and need not
be treated.
explanation: >-
The counterweight, and the reason this entry does not treat accumulation and
illness as the same thing.
downstream:
- target: Impaired Oxygen Delivery
causal_link_type: DIRECT
description: >-
Ferric haem cannot bind oxygen, so the carrying capacity falls in proportion
to the fraction converted.
- name: Reduced Oxygen Transport Reserve
description: >-
What the patient brings to the poisoning. The same methemoglobin fraction is
tolerated or not depending on whether oxygen transport was already impaired,
so a level that is asymptomatic in one patient warrants treatment in another.
Curated as a modifier on delivery rather than folded into it, because it
changes the threshold at which accumulation becomes illness without changing
the accumulation.
role: modifier
biological_scale: ORGANISM
evidence:
- reference: PMID:22024786
reference_title: "Methemoglobinemia: pathogenesis, diagnosis, and management."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
In the presence of comorbid conditions that impair oxygen transport,
however, low-grade methemoglobinemia can become symptomatic and may warrant
treatment.
explanation: >-
States the modifying effect and its clinical consequence, which is a change
in the treatment threshold rather than in the biochemistry.
- reference: PMID:22024786
reference_title: "Methemoglobinemia: pathogenesis, diagnosis, and management."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Typically, symptoms correlate with the methemoglobin level, and treatment
with methylene blue is reserved for patients with significantly elevated
methemoglobin levels.
explanation: >-
Gives the default the modifier departs from: symptoms usually track the
level, and this node is why sometimes they do not.
downstream:
- target: Impaired Oxygen Delivery
causal_link_type: DIRECT
description: >-
Less reserve means the same loss of carrying capacity produces more
shortfall.
- name: Impaired Oxygen Delivery
description: >-
Tissue hypoxia with a normal arterial oxygen tension, which is the
contradiction that identifies this disease. The oxygen is dissolved and
measurable; it is the carrier that is missing.
role: outcome
biological_scale: ORGANISM
evidence:
- reference: PMID:8416301
reference_title: "Concise review: methemoglobinemia."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The ferrous iron of hemoglobin is exposed continuously to high
concentrations of oxygen and, thereby, is oxidized slowly to methemoglobin,
a protein unable to carry oxygen.
explanation: >-
Supports the inability to carry oxygen that this node rests on. The source
states it as a property of the molecule rather than measuring delivery.
downstream:
- target: Cyanosis
causal_link_type: DIRECT
description: >-
Ferric haem gives the blood its colour change, which is why the cyanosis
appears without the oxygen tension falling.
- target: Dyspnea
causal_link_type: DIRECT
description: >-
Breathlessness from the fall in delivered oxygen.
- target: Metabolic acidosis
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
description: >-
Tissue hypoxia drives anaerobic metabolism. The intermediate is lactate, and
the cited source reports the acidosis as a possible finding without
assigning its origin.
discussions:
- discussion_id: darling_roughton_affinity_shift
kind: KNOWLEDGE_GAP
status: OPEN
prompt: >-
Does oxidation of part of the haemoglobin tetramer raise oxygen affinity at
the remaining ferrous sites, and if so does that contribute materially to the
hypoxia in this disease?
attaches_to:
- pathophysiology#Impaired Oxygen Delivery
rationale: >-
The standard account has two arms rather than one. Ferric haem cannot carry
oxygen, which is the arm this entry curates. The second arm, named the
Darling-Roughton effect, holds that oxidising part of a tetramer raises the
affinity of the ferrous subunits that remain, so the oxygen still carried is
released less readily and the dissociation curve shifts left. If that holds,
the patient loses delivery twice over and the hypoxia is worse than the
methemoglobin fraction alone predicts.
An earlier draft of this entry asserted the affinity shift in its description.
It was removed because none of the four references cited here states it, and
targeted searching did not find a source. It is recorded here rather than
dropped, because the effect is named in the secondary literature and the
oxygen delivery node would be a better model with it than without.
proposed_experiments:
- experiment_id: dissociation_curve_in_acquired_methemoglobinemia
name: Measure the oxygen dissociation curve against methemoglobin fraction
description: >-
Determine P50 across a range of methemoglobin fractions in human blood,
acquired rather than congenital, and test whether the shift exceeds what
loss of carrying capacity alone accounts for.
decision_criterion: >-
P50 falls as methemoglobin fraction rises, beyond the change predicted by
reduced functional haem alone.
supporting_outcome:
- The Impaired Oxygen Delivery node needs a second arm for impaired unloading,
and the hypoxia is worse than the fraction predicts.
refuting_outcome:
- Loss of carrying capacity is the whole of the delivery defect and the single
arm curated here is complete.
notes: >-
Raised from a falcon deep-research report that stated the effect as an ordered
step in its causal chain, citing sources this entry does not hold. The claim
may well be correct. It is not curated because it is not verified here.
differential_diagnoses:
- name: Hereditary methemoglobinemia
disease_term:
preferred_term: hereditary methemoglobinemia
term:
id: MONDO:0018963
label: hereditary methemoglobinemia
description: >-
The genetic phenocopy, and the closest one in this knowledge base because the
two diseases share their central node outright. Both end at accumulated
ferric haem and both present with cyanosis unresponsive to oxygen beside a
normal arterial oxygen tension. They arrive from opposite sides of one
balance: biallelic CYB5R3 variants remove the reductase, and an oxidant drug
outruns a reductase that works. No measurement of the methemoglobin itself
separates them.
distinguishing_features:
- Exposure history, and resolution when the exposure is removed
- Lifelong cyanosis from infancy in the hereditary form, against acute onset here
- Cytochrome b5 reductase activity, which is reduced in the hereditary form and
normal here
- CYB5R3 sequencing
evidence:
- reference: PMID:8416301
reference_title: "Concise review: methemoglobinemia."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
However, should methemoglobin formation be increased--e.g., due to the
presence of oxidant drugs, or an abnormal methemoglobin not amenable to
reduction (hemoglobin M), or a deficiency in red cell cytochrome b5
reductase--methemoglobinemia will result.
explanation: >-
One sentence naming both routes to the same endpoint, which is what makes
this a phenocopy rather than a resemblance.
- name: Hemoglobin M disease
description: >-
The third route named in the same sentence, and the one this entry does not
curate. A structurally abnormal haemoglobin holds iron in the ferric state and
is not amenable to reduction, so the reductase is neither absent nor outrun.
It is a third way to reach the same node and belongs on the list for that
reason.
distinguishing_features:
- Haemoglobin electrophoresis or sequencing
- No exposure history, and no response to methylene blue, since the lesion is in
the globin rather than in the reducing capacity
evidence:
- reference: PMID:8416301
reference_title: "Concise review: methemoglobinemia."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
However, should methemoglobin formation be increased--e.g., due to the
presence of oxidant drugs, or an abnormal methemoglobin not amenable to
reduction (hemoglobin M), or a deficiency in red cell cytochrome b5
reductase--methemoglobinemia will result.
explanation: >-
Names haemoglobin M as a distinct route. The non-response to methylene blue
in this entry's distinguishing features follows from where the lesion sits
and is not stated by this source.
- name: Cyanotic cardiac or pulmonary disease
description: >-
What the patient is usually assumed to have. Two bedside observations point
away from it: the patient looks better than the cyanosis suggests, and the
cyanosis does not improve on oxygen.
distinguishing_features:
- Cyanosis unresponsive to oxygen therapy
- Arterial blood gas showing a normal oxygen tension beside the cyanosis
- Pulse oximetry unreliable rather than simply low
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
the victim is often less unwell than one would expect from the severity of
'cyanosis' and, secondly, the 'cyanosis' is unresponsive to oxygen therapy
explanation: >-
Gives both discriminating observations, in the source's own framing as
clinical clues.
diagnosis:
- name: Recognition from cyanosis with a saturation gap
diagnosis_term:
preferred_term: bedside recognition of cyanosis with a saturation gap
term:
id: NCIT:C124351
label: Clinical Evaluation
description: >-
The diagnosis is a contradiction noticed at the bedside. The patient is
cyanosed and looks better than the cyanosis suggests, the cyanosis does not
improve on oxygen, and the blood is chocolate brown. Between the pulse
oximeter and the arterial gas there is a gap that should not exist.
results: >-
Cyanosis with a saturation gap and chocolate-brown blood raises the
suspicion; an elevated methemoglobin concentration confirms it.
evidence:
- reference: PMID:22024786
reference_title: "Methemoglobinemia: pathogenesis, diagnosis, and management."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Unique features, such as a saturation gap and chocolate-brown-colored blood,
can raise suspicion for methemoglobinemia.
explanation: >-
Names the two signs this diagnosis turns on. The sibling entry
Hereditary_Methemoglobinemia cites the same sentence, which is appropriate:
the diagnostic picture is shared and the exposure history is what separates
the two diseases.
- reference: PMID:22024786
reference_title: "Methemoglobinemia: pathogenesis, diagnosis, and management."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The diagnosis of methemoglobinemia should be considered in patients
presenting with cyanosis and hypoxia.
explanation: >-
States when to think of it at all, which is the step before any measurement.
- name: Pulse oximetry is unreliable
diagnosis_term:
preferred_term: pulse oximetry
term:
id: NCIT:C38085
label: Pulse Oximetry
description: >-
Curated as its own diagnostic entry because the instrument does not simply
read low, it reads wrongly, and a clinician who trusts it is misled rather
than merely uninformed. This is what creates the saturation gap against the
arterial gas.
results: >-
Oximetry readings cannot be used to gauge severity or response in this
disease.
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Pulse oximetry is unreliable in the presence of methaemoglobinaemia.
explanation: >-
States the unreliability directly. The entry's description and its cyanotic
cardiac differential both depend on this, and this is where it is now
carried.
- name: Arterial blood gas with co-oximetry
diagnosis_term:
preferred_term: arterial blood gas with co-oximetry
term:
id: NCIT:C217391
label: Diagnostic Blood Gas Testing
description: >-
The confirmatory test, and the one that makes the contradiction explicit. The
dissolved oxygen tension is normal, the calculated saturation is normal, and
the measured methemoglobin is raised. Normal numbers beside a blue patient are
the finding.
results: >-
Normal pO2 and calculated saturation with an increased methemoglobin
concentration, and possibly a metabolic acidosis.
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Arterial blood gas analysis is mandatory in severe poisoning and reveals
normal partial pressures of oxygen (pO2) and carbon dioxide (pCO2,), a
normal 'calculated' haemoglobin oxygen saturation, an increased
methaemoglobin concentration and possibly a metabolic acidosis.
explanation: >-
Gives the full expected panel, including the normal values that make the
raised methemoglobin interpretable.
- name: Exposure history
diagnosis_term:
preferred_term: oxidant exposure history
term:
id: NCIT:C124351
label: Clinical Evaluation
description: >-
What separates this disease from its genetic phenocopy, and the source is
blunt that taking it makes the diagnosis straightforward. Dapsone and
benzocaine are the common culprits among medications.
results: >-
A history of an oxidant drug, chemical or occupational exposure, absent in the
hereditary form.
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
If an occupational history is taken, the diagnosis of methaemoglobinaemia
should be relatively straightforward.
explanation: >-
States the diagnostic value of the history, with the conditional that makes
it a failure of asking rather than of testing.
- reference: PMID:22024786
reference_title: "Methemoglobinemia: pathogenesis, diagnosis, and management."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
A variety of frequently used medications are capable of inducing
methemoglobinemia, with dapsone and benzocaine being common culprits.
explanation: >-
Names the two commonest medication culprits, which is what the history is
looking for.
notes: >-
Bound to NCIT:C124351 Clinical Evaluation rather than a procedure term,
because taking a history is not a coded procedure and no more specific NCIT
class fits. The same applies to the cyanosis recognition entry. The two
instrument-based entries in this section are bound to their own procedure
terms, NCIT:C38085 and NCIT:C217391, because the diagnostic identity of this
disease is that those two measurements disagree, and a shared generic binding
would leave that distinction in the entry names and nowhere a query could
reach it.
phenotypes:
- name: Cyanosis
description: >-
Present out of proportion to how ill the patient looks, and unresponsive to
oxygen. Both features are diagnostic rather than incidental.
phenotype_term:
preferred_term: Cyanosis
term:
id: HP:0000961
label: Cyanosis
temporality: ACUTE
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
the victim is often less unwell than one would expect from the severity of
'cyanosis' and, secondly, the 'cyanosis' is unresponsive to oxygen therapy
explanation: >-
Gives both qualifiers this phenotype is described by.
- name: Hemolytic anemia
description: >-
Seen with the higher methemoglobin levels, and with some oxidant chemicals it
is the greater danger. The source is explicit that not every feature of a
poisoned patient belongs to the methemoglobin.
phenotype_term:
preferred_term: Hemolytic anemia
term:
id: HP:0001878
label: Hemolytic anemia
temporality: ACUTE
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Not all features observed in patients with methaemoglobinaemia are due to
methaemoglobin formation.
explanation: >-
Supports separating the haemolysis from the methemoglobin rather than
treating it as downstream of it. The source names chlorates as the example
where the haemolysis is the greater risk.
- reference: PMID:21852596
reference_title: "Dapsone-induced methemoglobinemia: a primer for clinicians."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Delayed hemolytic anemia was seen in patients with high methemoglobin levels
at presentation.
explanation: >-
Associates the haemolysis with higher methemoglobin at presentation in the
dapsone series, and notes its delayed timing.
- name: Metabolic acidosis
phenotype_term:
preferred_term: Metabolic acidosis
term:
id: HP:0001942
label: Metabolic acidosis
temporality: ACUTE
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Arterial blood gas analysis is mandatory in severe poisoning and reveals
normal partial pressures of oxygen (pO2) and carbon dioxide (pCO2,), a
normal 'calculated' haemoglobin oxygen saturation, an increased
methaemoglobin concentration and possibly a metabolic acidosis.
explanation: >-
Names the acidosis as a possible finding, alongside the normal oxygen
tension that makes the picture recognisable.
- name: Dyspnea
phenotype_term:
preferred_term: Dyspnea
term:
id: HP:0002094
label: Dyspnea
temporality: ACUTE
evidence:
- reference: PMID:21852596
reference_title: "Dapsone-induced methemoglobinemia: a primer for clinicians."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Excluding overdose situations, 18 described symptomatic dapsone-associated
methemoglobinemia and clinical presentation ranging from cyanosis to
dyspnea.
explanation: >-
Gives the symptomatic range in the dapsone case series.
progression:
- phase: Delayed onset after low-level exposure
duration: hours to days
notes: >-
Not every case declares quickly. Where exposure is to low concentrations, by
inhalation or repeated skin contact, features build over hours or days. That
matters clinically because the exposure may have stopped before the patient
presents, and because a single reassuring measurement early does not settle
the question.
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Features of toxicity may develop over hours or even days when exposure,
whether by inhalation or repeated skin contact, is to relatively low
concentrations of inducing chemical(s).
explanation: >-
Gives the timescale and the exposure conditions that produce it.
environmental:
- name: Oxidant drug or chemical exposure
description: >-
A heterogeneous set that sorts by oxidation route rather than by drug class.
Nitrites act by co-oxidation. Aromatic amino and nitro compounds act after
biotransformation to an active intermediate, and their lipophilicity and
volatility make skin and inhalation the routes that matter at work. Dapsone
is the recurring therapeutic culprit, and it does this at therapeutic doses
rather than only in overdose.
exposure_term:
preferred_term: exposure to oxidant drug or chemical
term:
id: ECTO:0000509
label: exposure to drug
exposure_classifications:
hazard_agent_type:
- classification_value: CHEMICAL
exposure_route:
- classification_value: ORAL
- classification_value: DERMAL
- classification_value: INHALATION
influences_mechanisms:
- target: Systemic Oxidant Exposure
environmental_effect: TRIGGERS
causal_link_type: DIRECT
description: >-
Exposure is what raises the rate of formation past the recovery capacity.
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Aromatic compounds are responsible for most cases, their lipophilic nature
and volatility facilitating absorption during dermal and inhalational
exposure, the principal routes implicated in the workplace.
explanation: >-
Names the dominant chemical class and the routes, which is what the
exposure_classifications record.
evidence:
- reference: PMID:21852596
reference_title: "Dapsone-induced methemoglobinemia: a primer for clinicians."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the majority of publications describing methemoglobinemia associated with
dapsone use reported this adverse effect at therapeutic doses
explanation: >-
Establishes that a therapeutic dose is enough, which is why this is a drug
toxicity and not only a poisoning.
- reference: PMID:22024786
reference_title: "Methemoglobinemia: pathogenesis, diagnosis, and management."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
A variety of frequently used medications are capable of inducing
methemoglobinemia, with dapsone and benzocaine being common culprits.
explanation: >-
Names benzocaine alongside dapsone. The local anaesthetics are a culprit
class this entry otherwise did not carry, and they matter because the
exposure is topical and often incidental to a procedure.
notes: >-
Bound to ECTO:0000509 exposure to drug, which covers the therapeutic culprits
and not the occupational chemicals or the well water that also cause this
disease. ECTO was searched through this repository's adapter
(sqlite:obo:ecto) and has no class for an oxidant chemical as a group. The
entry keeps one exposure record rather than splitting by route, because the
sources sort the culprits by oxidation mechanism rather than by setting.
treatments:
- name: Methylene blue
description: >-
The antidote, and one whose mechanism carries its own contraindication. It
works by being reduced inside the red cell and then handing that reduction to
ferric haem, and the reducing power comes from NADPH. So the antidote depends
on a pathway the patient may not have. In glucose-6-phosphate dehydrogenase
deficiency it is less effective or ineffective, and in the presence of
haemolysis a high dose can make methemoglobin instead of clearing it. The
same oxidising chemistry that treats the disease can cause it.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: methylene blue
term:
id: CHEBI:6872
label: methylene blue
target_mechanisms:
- target: Methemoglobin Accumulation
treatment_effect: INHIBITS
description: >-
Accelerates the conversion of ferric haem back to ferrous, roughly six-fold
over the intrinsic rate. It acts on the accumulated pool rather than on the
oxidant, so it does not stop ongoing formation while exposure continues.
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
clinical experience suggests that methylene blue can increase the rate of
methaemoglobin conversion to haemoglobin some 6-fold
explanation: >-
Gives the magnitude of the effect. Note the source's own hedge: this is
clinical experience, and the same review states that no controlled trial
of efficacy has been performed.
evidence:
- reference: PMID:34463662
reference_title: "Methylene Blue: An Antidote for Methemoglobinemia and Beyond."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Methylene blue has been in medicinal use for centuries and is best known as
an antidotal treatment for acquired methemoglobinemia (MetHB).
explanation: >-
Establishes the antidotal role in this disease specifically.
- reference: PMID:34463662
reference_title: "Methylene Blue: An Antidote for Methemoglobinemia and Beyond."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Methylene blue's mechanism of action is somewhat complex and based partly on
its oxidizing capabilities, ironically the same mechanism that causes MetHB.
explanation: >-
Supports the description's point that the antidote and the poison share
chemistry, which is what makes the high-dose reversal possible.
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Patients with features and/or methaemoglobin concentrations of 30-50%,
should be administered methylene blue 1-2 mg/kg/bodyweight intravenously
explanation: >-
Gives the treatment threshold and dose.
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Symptomatic improvement usually occurs within 30 minutes
explanation: >-
Gives the expected time to response, which is what makes a non-response
informative.
notes: >-
The NADPH dependence stated in this description is the mechanism behind the
G6PD contraindication, and the cited source gives it as a dependence on NADP+
rather than tracing the pathway to glucose-6-phosphate dehydrogenase. The
entry does not assert the pentose phosphate pathway step, which no source
cited here states.
- name: Methylene blue failure in G6PD deficiency
description: >-
Curated as a treatment entry in its own right, because a patient who does not
respond to the antidote is a recognisable clinical situation with its own
management rather than an absence of treatment. Methylene blue is less
effective or ineffective here, and at high dose in the presence of haemolysis
it can generate methemoglobin. Exchange transfusion is what the source offers
instead.
therapeutic_modality: OTHER
treatment_term:
preferred_term: Therapeutic Procedure
term:
id: NCIT:C49236
label: Therapeutic Procedure
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: REFUTE
evidence_source: OTHER
snippet: >-
Methylene blue is less effective or ineffective in the presence of
glucose-6-phosphate dehydrogenase deficiency since its antidotal action is
dependent on nicotinamide-adenine dinucleotide phosphate (NADP+).
explanation: >-
Curated as REFUTE against the proposition that methylene blue treats this
disease in a G6PD-deficient patient, with the reason given.
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
in the presence of haemolysis, high dose methylene blue (20-30 mg/kg) can
itself initiate methaemoglobin formation
explanation: >-
Establishes the dose-dependent reversal, which is why the failure is not
merely a lack of benefit.
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Exchange transfusion may have a role in the management of severe haemolysis
or in G-6-P-D deficiency associated with life-threatening
methaemoglobinaemia where methylene blue is relatively contraindicated.
explanation: >-
Gives the alternative, and the source's own framing of the contraindication
as relative rather than absolute.
- name: Exposure removal, decontamination and high-flow oxygen
description: >-
The measures that address the production side rather than the pool. Removing
the oxidant is what allows an intact reductase to win the balance back, which
is the reason this disease resolves and the hereditary one does not. Oxygen
does not correct the cyanosis, and is given to make the most of the ferrous
haem that remains.
therapeutic_modality: OTHER
treatment_term:
preferred_term: Supportive Care
term:
id: NCIT:C15747
label: Supportive Care
target_mechanisms:
- target: Systemic Oxidant Exposure
treatment_effect: INHIBITS
description: >-
Removing the exposure stops the accelerated formation at its source.
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Following decontamination, high-flow oxygen should be given to maximise
oxygen carriage by remaining ferrous haem.
explanation: >-
Places decontamination first and states what the oxygen is for, which is
the distinction this treatment is built on.
- name: Ascorbic acid, N-acetylcysteine and tocopherol
description: >-
Curated as treatments without confirmed benefit. They are used as adjuvants or
alternatives to methylene blue, which makes them worth recording, and the
cited review says plainly that the benefit is unconfirmed.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: PMID:14579544
reference_title: "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue."
supports: REFUTE
evidence_source: OTHER
snippet: >-
Supplemental antioxidants such as ascorbic acid (vitamin C),
N-acetylcysteine and tocopherol (vitamin E) have been used as adjuvants or
alternatives to methylene blue with no confirmed benefit.
explanation: >-
An explicit statement of unconfirmed benefit, curated as REFUTE against the
claim that these agents treat the disease.
Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.
Create: Drug-Induced Methemoglobinemia · 2026-09-02T18:12:42Z · View source
New entry for drug-induced methemoglobinemia (MONDO:0018740), the second case curated from the shared Toxicologic Phenocopy Atlas. Chosen because it is the only remaining Tier 1 pair in that atlas with a specific MONDO term whose genetic sibling is already in this KB: Hereditary_Methemoglobinemia (MONDO:0018963). Vigabatrin, leflunomide and the loop/thiazide diuretic pairs are equally clean mechanistically and have no MONDO disease term, so they cannot be entries; warfarin embryopathy has only an obsolete term. Modelled as a balance rather than as a lesion. Three decisions carry the entry: 1. Baseline autoxidation and reductase recovery capacity are separate nodes, both entry points. Ferrous haem is oxidised continuously and the reductase drains the pool so efficiently that circulating methemoglobin is negligible. Without both nodes the disease reads as an abnormality appearing rather than an existing balance losing on the production side. This is what makes the phenocopy structural: the hereditary disease loses the reductase, this one outruns one that works, and the two share the accumulation node outright. PMID:8416301 names both routes and a third in a single sentence, which is quoted on the capacity node and on two differentials. 2. Haemolytic anaemia hangs off the oxidant exposure node, NOT off methemoglobin accumulation. PMID:14579544 states that not all features observed in these patients are due to methemoglobin formation, and names chlorates as a case where the haemolysis is the greater threat to life. Drawing that edge from the accumulation would assert a causal claim the source contradicts. The edge description says so explicitly. 3. Methylene blue failure in G6PD deficiency is a treatment entry in its own right rather than a caveat in notes. The antidote's action depends on NADP+, so it is less effective or ineffective in G6PD deficiency, and at high dose in the presence of haemolysis it can generate methemoglobin itself. That is curated with a REFUTE evidence item against the proposition that methylene blue treats this disease in such a patient, plus exchange transfusion as the alternative the source offers. A patient who does not respond to the antidote is a recognisable clinical situation with its own management, not an absence of treatment. The oxidant exposure node keeps the three oxidation routes the source distinguishes (direct oxidation, co-oxidation as in nitrites, and biotransformation to an active intermediate as in aromatic amino and nitro compounds) rather than listing culprit chemicals, because the sources sort them by route. Differentials: hereditary methemoglobinemia (the phenocopy), haemoglobin M disease (the third route to the same node, not curated as an entry), and cyanotic cardiac or pulmonary disease (what the patient is usually assumed to have, with the two bedside observations that point away from it). Evidence: 41 items over 5 references, all pre-verified against the local cache before writing except four in the phenotype and exposure blocks, which were written first and verified after; they passed, and the sequence was wrong. Anchors are PMID:14579544 (occupational review, which supplies the oxidation routes, the G6PD contraindication, the high-dose reversal, the negative evidence on antioxidant adjuvants and the exchange transfusion alternative), PMID:8416301 (the balance and the phenocopy sentence), PMID:34463662 (methylene blue, and that its antidotal chemistry is the same chemistry that causes the disease), and PMID:21852596 (dapsone at therapeutic doses, and the delayed haemolysis). Claims deliberately not made: the six-fold methylene blue figure carries the source's own hedge that it is clinical experience and that no controlled trial of efficacy has been performed. The NADPH dependence is stated as the source states it, as a dependence on NADP+, without asserting the pentose phosphate pathway step that no cited source names. The metabolic acidosis edge is INDIRECT_KNOWN_INTERMEDIATES because the source reports the acidosis without assigning its origin. PMID:17379039 was fetched and not cited: no abstract. MONDO:0018740 was seeded from the local sqlite adapter after an OLS timeout, and conf/oak_config.yaml was restored and verified clean afterwards. Validation: just validate-disorders (the batched sweep CI runs) passed; 41/41 snippets verified; check-folded-hyphens, check-duplicate-keys, check-title-snippets, check-environmental-evidence and check-entity-refs all clean; 36 tests pass; graph checked for dangling targets and unwired phenotypes, none, with the two balance nodes as intentional entry points. All reference_title values generated programmatically from the cache. Granularity pass after the first draft, at the user's request, to remove bundling from the pathophysiology. Three findings, in descending order of consequence. 1. `Oxidant Exposure and Accelerated Haem Oxidation` was one node carrying the exposure plus three mechanistically distinct oxidation routes. Split into `Systemic Oxidant Exposure`, `Biotransformation to an Oxidising Intermediate` and the oxidation nodes. Biotransformation earns its own node because the parent compound is inert toward haem and the metabolism is what makes it dangerous, which is a different claim from oxidising haem. 2. Direct oxidation and co-oxidation were then merged into one node with a `notes` block defending the merge. The defence was weak and the merge was undone. The two have OPPOSITE oxygen requirements, direct proceeding most readily in the absence of oxygen and co-oxidation requiring haemoglobin-bound oxygen, and both statements are quotable. That is a real distinction, so it earns two nodes, and the oxygen dependence is now carried as evidence rather than as prose. 3. THE TOP-LEVEL DESCRIPTION ASSERTED A CLAIM NOTHING IN THE ENTRY CARRIED. It said ferric haem "distorts the remaining ferrous subunits so they release what they carry less readily". No node held it, no evidence supported it, and none of the four references states it. This is the third occurrence of the same defect in this session, in a third slot: isoniazid was description against notes, ackee was a differential's description against its own snippet, and this was the disease description against the whole entry. The claim was removed. The falcon report then returned that claim with a name, the Darling-Roughton effect, as an ordered step in its causal chain, citing sources this entry does not hold. Targeted searching found no citable primary source. It is curated as a KNOWLEDGE_GAP attached to `Impaired Oxygen Delivery`, with an experiment that would settle it and a note recording that the claim may well be correct and is simply not verified here. The same call as MCPG in the ackee entry. Final pathograph: 8 nodes, one claim each, no name joining two things, no dangling targets. The two entry points without inbound edges are the two arms of the balance, which is intentional. Deep research: falcon via Edison, 104 KB, zero PMIDs (normal for falcon, which cites by DOI), 14/14 references resolved, 0 unresolved, 0 off topic. Exit code 3 was a term-validation OLS timeout on HP:0012378, not a content failure. NEC preflight SKIP, cleared manually: top gene mentions were G6PD, CYB5R3 and CYB5A, with G6PD leading, which is the right profile and confirms the antidote failure belongs in the entry rather than in a footnote. Not taken from the report for want of a source I hold: a 2024 cohort with per-agent case counts, and rebound methemoglobinemia after methylene blue with dapsone requiring repeat dosing. Both are worth having and neither is curated on the report's authority. Review round 1 (ai4c-reviewer, CHANGES_REQUESTED) raised two items. Both correct, and the second exposed a false statement I made in the PR body. 1. No diagnosis: section, while the disease description asserted "a pulse oximeter that cannot be trusted" and the cyanotic-cardiac differential turned on oximetry being unreliable rather than low. This is the FOURTH occurrence in this session of asserting in prose what the entry does not carry, and the sharpest one: I pre-verified the exact supporting sentence ("Pulse oximetry is unreliable in the presence of methaemoglobinaemia.") earlier in the same session, then never used it. Verifying a quote and writing a claim that depends on it are two acts, and I did them separately and never joined them. Four diagnosis entries added: recognition from cyanosis with a saturation gap, the oximetry unreliability as its own entry, arterial blood gas with co-oximetry, and exposure history. 2. PMID:22024786 (Skold et al.) has been committed in references_cache/ since the hereditary entry was curated, and I did not check what the repository already held. The PR body said material was "not curated for want of a source I hold", which was false: the source was on main. Three claims it supports are now curated. The saturation gap and chocolate-brown blood in the diagnosis section; benzocaine named alongside dapsone as a culprit, which adds the local anaesthetic class the entry lacked; and a new Reduced Oxygen Transport Reserve modifier node, because the same methemoglobin fraction is tolerated or not depending on whether oxygen transport was already impaired, which changes the treatment threshold without changing the biochemistry. Also taken from the suggestions: a progression: record for delayed onset over hours to days after low-level inhalational or repeated dermal exposure, quotable from PMID:14579544 and clinically load-bearing, since the exposure may have ended before the patient presents. Final pathograph: 9 nodes. Three entry points without inbound edges, which are the two arms of the balance and the reserve modifier. Process note for the next entry: before writing, check what is already in references_cache/ for the disease and its siblings. Two of this round's items were closed with a reference the repository had all along, and one of them I had already verified a quote from. Review round 2 (ai4c-reviewer, CHANGES_REQUESTED) confirmed both round-1 items closed and raised one new item, which was a good catch about this entry's own reasoning rather than about coverage. All four diagnosis_term bindings were NCIT:C124351 Clinical Evaluation with preferred_term "clinical assessment". Two of the four name procedures NCIT codes specifically, and both codes were already committed here, enum-proven, and already used as diagnosis_term in other entries. The point that matters: this entry splits pulse oximetry from arterial blood gas into separate diagnosis entries BECAUSE the diagnostic identity of the disease is that those two measurements disagree, and then bound both to the same generic term, so the distinction survived only in the entry names and nowhere a query could reach it. Pulse oximetry is now NCIT:C38085 and the blood gas is NCIT:C217391, both verified cached and enum-valid before use. The two entries that remain on NCIT:C124351 are recognition from cyanosis and exposure history. Taking a history is not a coded procedure and no more specific class fits, and a note on the exposure-history entry records that choice alongside the reason the other two were made specific, so the generic bindings read as decisions rather than as the same oversight repeated. The four preferred_term values were also paraphrases of the broad label, less specific than the entries they described, so they recovered nothing the binding dropped. All four replaced.
Scope. This report treats drug-induced methemoglobinemia as an acquired toxic/iatrogenic dyshemoglobinemia, not as congenital CYB5R3 deficiency or hemoglobin-M disease. Evidence is principally aggregated disease-level literature, hospital cohorts, trials, and case series; the 2024 Iowa study used de-identified individual medical-record data aggregated at cohort level. No patient-specific EHR data were supplied for this report. (iolascon2021recommendationsfordiagnosis pages 1-3, belzer2024causesofacquired pages 1-2)
Drug-induced methemoglobinemia occurs when a medication or reactive metabolite oxidizes hemoglobin iron from oxygen-binding ferrous Fe²⁺ to ferric Fe³⁺ faster than erythrocyte reduction systems can restore it. Ferric heme cannot bind oxygen, while oxidation also increases oxygen affinity at the remaining ferrous hemes, producing functional anemia and impaired tissue unloading despite a normal arterial oxygen tension. It is usually acute, reversible, and exposure-dependent, but dapsone and lipophilic agents can produce delayed or recurrent toxicity. (iolascon2021recommendationsfordiagnosis pages 1-3, belzer2024causesofacquired pages 1-2, iolascon2021recommendationsfordiagnosis pages 9-10)
The strongest recent epidemiologic evidence is a 2024 single-center retrospective study: among 21,449 measurements from 2,502 patients during 2009–2023, 546 measurements (2.5%) were ≥3.1% MetHb and 33 (0.15%) were ≥10%. Dapsone caused 67.0% of pediatric and 63.6% of adult elevated-MetHb encounters; inhaled nitric oxide caused 16.5% and 12.8%, respectively. These are proportions among tested hospital patients, not population incidence estimates. (belzer2024causesofacquired pages 1-2, belzer2024causesofacquired pages 3-4, belzer2024causesofacquired pages 2-3)
The operational clinical summary is provided below.
| Domain | High-value finding | Quantitative threshold/data | Ontology suggestion |
|---|---|---|---|
| Normal physiology | Methemoglobin (MetHb) is continuously generated but normally reduced within erythrocytes | Usually <1%–2% of total hemoglobin | GO:0019825 oxygen binding; CL:0000232 erythrocyte |
| Severity: minimal | Low pulse-oximeter readings or pale, gray, or blue skin may occur; patients are generally asymptomatic | MetHb <10% | HP:0012418 hypoxemia; HP:0032239 abnormal blood oxygen level |
| Severity: mild | Cyanosis and dark-brown or chocolate-colored blood; asymptomatic status or confusion is possible | MetHb 10%–30% | HP:0000961 cyanosis; HP:0001289 confusion |
| Severity: moderate | Functional anemia causes dyspnea, dizziness, syncope, chest pain, palpitations, headache, and fatigue | MetHb 30%–50% | HP:0002094 dyspnea; HP:0002321 vertigo; HP:0001279 syncope; HP:0001695 palpitations; HP:0002315 headache; HP:0012378 fatigue |
| Severity: severe | Tachypnea, metabolic acidosis, dysrhythmia, seizure, delirium, or coma may develop | MetHb 50%–70% | HP:0002789 tachypnea; HP:0001942 metabolic acidosis; HP:0011675 arrhythmia; HP:0001250 seizure; HP:0001259 coma |
| Severity: potentially fatal | Profound tissue hypoxia and death; urgent rescue treatment is required | MetHb >70% | HP:0012418 hypoxemia; GO:0070482 response to oxygen levels |
| Diagnostic clue | Suspect when cyanosis or low SpO₂ fails to correct with supplemental oxygen despite a normal or high PaO₂ | SpO₂ often trends toward ~85%; a saturation gap >5% is suggestive | HP:0000961 cyanosis; HP:0012418 hypoxemia |
| Confirmatory test | Multiwavelength blood co-oximetry directly quantifies MetHb and is preferred over conventional pulse oximetry | Report MetHb as percentage of total hemoglobin; arterial or venous blood may be used | LOINC: methemoglobin/total hemoglobin in blood; NCIT: C111159 Co-Oximetry |
| Visual finding | Blood remains chocolate-brown rather than becoming red after oxygen exposure | Commonly apparent with clinically important MetHb, often >10%–20% | HP:0031816 abnormal blood color |
| Key drug triggers | Dapsone, benzocaine, prilocaine, lidocaine, phenazopyridine, primaquine/chloroquine, sulfonamides, rasburicase, metoclopramide, nitroglycerin, nitroprusside, and inhaled nitric oxide | Risk is exposure- and dose-dependent; dapsone and inhaled nitric oxide predominate in monitored hospital populations | CHEBI terms for individual oxidants; NCIT: Pharmacologic Substance |
| Other triggers | Sodium/amyl/isobutyl nitrite, nitrate-contaminated food or water, aniline/nitrobenzene, chlorates, pesticides, smoke inhalation, and some recreational-drug adulterants | Intentional nitrite ingestion can produce MetHb >30% and fatal poisoning | CHEBI:16301 nitrite; CHEBI:17632 nitrate; NCIT: Environmental Exposure |
| Initial management | Stop or remove the oxidant, administer oxygen, obtain IV access, correct acidosis/hypoglycemia, and provide cardiopulmonary or seizure support as required | Treat the patient immediately when unstable; do not delay care while distinguishing acquired from hereditary disease | NCIT: C71943 Supportive Care; NCIT: Oxygen Therapy |
| Treatment threshold | Methylene blue is indicated for symptomatic acquired disease and for high levels even without symptoms; lower thresholds apply when oxygen delivery is already compromised | Common thresholds: ≥20% if symptomatic or ≥30% if asymptomatic; consider treatment near 10% with severe anemia or cardiac/pulmonary disease | NCIT: Methylene Blue Treatment; CHEBI:6872 methylene blue |
| First-line antidote | IV methylene blue accepts electrons from NADPH; leukomethylene blue reduces ferric Fe³⁺ back to ferrous Fe²⁺ in erythrocytes | 1–2 mg/kg IV over 3–5 min | CHEBI:6872 methylene blue; GO:0055114 oxidation-reduction process |
| Repeat and maximum dosing | Repeat only if clinical findings or MetHb fail to improve; excessive dosing can worsen MetHb and cause hemolysis | Repeat 1 mg/kg after 30–60 min; avoid cumulative doses >5.5–7 mg/kg | NCIT: Repeat Dose; HP:0001878 hemolytic anemia |
| G6PD caution | Methylene blue may be ineffective and can provoke oxidative hemolysis because NADPH generation is impaired | Avoid when G6PD deficiency is known; rapidly weigh risk versus benefit in life-threatening poisoning | HP:0001878 hemolytic anemia; GO:0004345 glucose-6-phosphate dehydrogenase activity; CL:0000232 erythrocyte |
| Serotonergic-drug caution | Methylene blue inhibits monoamine oxidase A and may precipitate serotonin syndrome with serotonergic medicines | Review SSRIs, SNRIs, MAO inhibitors, and other serotonergic agents before administration when feasible | HP:0011447 serotonin syndrome; GO:0004491 monoamine oxidase activity |
| Alternative or adjunctive therapy | Ascorbic acid reduces MetHb nonenzymatically but acts more slowly; dosing is not standardized | Often requires ≥24 h; reported adult regimens vary from 0.5 g every 12 h to larger IV doses | CHEBI:29073 L-ascorbic acid; GO:0016209 antioxidant activity |
| Refractory disease | Exchange transfusion, red-cell transfusion, or hyperbaric oxygen may be used when methylene blue is contraindicated or ineffective | Therapeutic whole-blood exchange has reported 81.6% survival in methylene-blue-refractory cases | NCIT: C15283 Exchange Transfusion; NCIT: C135060 Hyperbaric Oxygen Therapy |
| Rebound monitoring | Long-acting or lipophilic oxidants can cause recurrent MetHb after an initial response; dapsone is especially important because of active metabolites and enterohepatic recirculation | Rebound may occur for up to 18 h; dapsone cases may require repeat treatment every 6–8 h for 2–3 days | NCIT: Therapeutic Drug Monitoring; HP:0031796 recurrent symptom |
| Clinical course | Most recognized and promptly treated episodes resolve completely after withdrawal of the trigger and restoration of functional hemoglobin | MetHb should decline substantially within 30–60 min after effective methylene blue | MONDO: acquired methemoglobinemia; GO:0036293 response to decreased oxygen levels |
Table: This table consolidates severity strata, diagnostic clues, common oxidant triggers, antidotal treatment, contraindications, rescue options, and rebound monitoring for drug-induced methemoglobinemia. It is based on expert recommendations, recent hospital data, and clinical reviews (iolascon2021recommendationsfordiagnosis pages 3-5, belzer2024causesofacquired pages 1-2, iolascon2021recommendationsfordiagnosis pages 9-10, iolascon2021recommendationsfordiagnosis pages 10-11, iolascon2021recommendationsfordiagnosis pages 8-9, cefalu2020methemoglobinemiainthe pages 6-8).
Methemoglobinemia is an excess of hemoglobin containing ferric iron. Healthy blood generally contains <1%–2% MetHb. “Drug-induced methemoglobinemia” denotes an acquired form attributable to a medicine, medical gas, or its metabolite; overlapping labels include acquired methemoglobinemia, toxic methemoglobinemia, toxin-induced methemoglobinemia, iatrogenic methemoglobinemia, and British spellings methaemoglobinaemia/methaemoglobinaemia. (iolascon2021recommendationsfordiagnosis pages 5-6, belzer2024causesofacquired pages 1-2)
A concise authoritative abstract statement is: “Acquired forms are the most common, mainly due to the exposure to substances that cause oxidation of the Hb both directly or indirectly.” This comes from the European Hematology Association/EuroBloodNet consensus review, published September 2021 (DOI: 10.1002/ajh.26340). (iolascon2021recommendationsfordiagnosis pages 1-3)
Prominent drug causes include dapsone, benzocaine, prilocaine, lidocaine, phenazopyridine, primaquine/chloroquine, sulfonamides including trimethoprim-sulfamethoxazole, rasburicase, metoclopramide, nitroglycerin, sodium nitroprusside, and inhaled nitric oxide. Less frequent reports involve acetaminophen overdose, phenacetin, nitrofurantoin, cyclophosphamide, flutamide, and even excessive methylene blue. Non-drug oxidants include sodium/amyl/isobutyl nitrite, nitrate-contaminated food or water, aniline/nitrobenzene, chlorates, pesticides, and smoke. (cefalu2020methemoglobinemiainthe pages 4-6, belzer2024causesofacquired pages 2-3, iolascon2021recommendationsfordiagnosis pages 11-12, cefalu2020methemoglobinemiainthe pages 8-10)
Dapsone is bioactivated to dapsone hydroxylamine, which oxidizes hemoglobin; enterohepatic recirculation and persistent metabolites explain prolonged or recurrent disease. Cimetidine can inhibit CYP-mediated hydroxylamine formation, but evidence supports neither routine acute use nor a universally accepted preventive regimen. (bai2024dapsoneinducedmethemoglobinemiain pages 3-4, barclay2011dapsoneinducedmethemoglobinemiaa pages 5-5, cefalu2020methemoglobinemiainthe pages 6-8)
Risk reflects oxidant potency, dose, route, duration, and absorption. Topical benzocaine on mucosa and high-dose prilocaine are particularly recognized procedural risks. Infants have only approximately 50%–60% of adult erythrocyte CYB5R activity and more readily oxidized HbF. Older age, anemia, acidosis, sepsis, pregnancy, and cardiac, pulmonary, coronary, peripheral vascular, or cerebrovascular disease lower tolerance by reducing oxygen-delivery reserve. (belzer2024causesofacquired pages 2-3, cefalu2020methemoglobinemiainthe pages 3-4, iolascon2021recommendationsfordiagnosis pages 8-9)
Genetic susceptibility is not equivalent to genetic causation. G6PD deficiency impairs NADPH generation, increases oxidative-hemolysis risk, and can make methylene blue ineffective or harmful. Unrecognized CYB5R3 deficiency, HbM, or unstable globin variants may amplify or mimic an acquired episode. No validated GWAS susceptibility loci, penetrance estimate, polygenic score, or clinically established pharmacogenomic dosing algorithm was identified. (iolascon2021recommendationsfordiagnosis pages 3-5, iolascon2021recommendationsfordiagnosis pages 9-10)
Avoidance or dose limitation of oxidants, alternative local anesthetics, monitoring during dapsone or inhaled-NO therapy, and preservation of glucose/NADPH availability are practical protective factors. The clearest gene–environment interaction is oxidant exposure superimposed on G6PD or erythrocyte reductase deficiency. A CYB5R3 Thr117Ser polymorphism has been discussed in malaria/sickle-cell contexts, but it is not an established protective allele for drug-induced methemoglobinemia. No protective diet or lifestyle intervention has proven efficacy. (iolascon2021recommendationsfordiagnosis pages 3-5, iolascon2021recommendationsfordiagnosis pages 9-10, iolascon2021recommendationsfordiagnosis pages 11-12)
Severity varies with MetHb percentage, rate of rise, hemoglobin concentration, comorbidity, and chronic adaptation. The consensus ranges are: <10%, usually asymptomatic with low oximeter readings or gray/blue color; 10%–30%, cyanosis and dark-brown blood, sometimes confusion; 30%–50%, dyspnea, dizziness, syncope, chest pain, palpitations, headache, and fatigue; 50%–70%, tachypnea, acidosis, dysrhythmia, seizure, delirium, or coma; >70%, profound hypoxia and high mortality. (iolascon2021recommendationsfordiagnosis pages 3-5, belzer2024causesofacquired pages 2-3)
Suggested HPO mappings include Cyanosis HP:0000961, Dyspnea HP:0002094, Headache HP:0002315, Fatigue HP:0012378, Syncope HP:0001279, Palpitations HP:0001695, Metabolic acidosis HP:0001942, Seizure HP:0001250, Coma HP:0001259, Hemolytic anemia HP:0001878, and hypoxemia/abnormal blood oxygenation. Chocolate-brown blood is best represented as an abnormal blood-color finding if the local terminology supports it.
Onset is possible at any age and is ordinarily abrupt after exposure. Manifestations are episodic and exposure-linked, rather than developmentally progressive. Quality-of-life instruments specific to this condition have not been validated; acute dyspnea, fatigue, confusion, intensive-care admission, and interruption of necessary dapsone therapy are the principal functional burdens. In the 2024 cohort, 68.7% of pediatric and 37.4% of adult elevated-MetHb encounters were asymptomatic, reflecting surveillance of treated patients. (belzer2024causesofacquired pages 4-5)
There is no single causal gene for the acquired target disease and no characteristic germline, somatic, chromosomal, or epigenetic lesion. Accordingly, pathogenic-variant classification, allele frequency, anticipation, mosaicism, and founder effects are not applicable to uncomplicated drug-induced disease.
Genes relevant to susceptibility and differential diagnosis are:
Routine WES, WGS, CMA, karyotyping, FISH, mtDNA, or repeat-expansion testing has no role after a clear exposure-linked, resolving episode. Consider CYB5R activity and targeted CYB5R3/globin sequencing when cyanosis predates exposure, persists after drug withdrawal, recurs without oxidants, or clusters in a family. (iolascon2021recommendationsfordiagnosis pages 5-6, iolascon2021recommendationsfordiagnosis pages 8-9)
Relevant environments include endoscopy/anesthesia and dental settings using topical/local anesthetics; ICUs using inhaled nitric oxide or nitroprusside; oncology/transplant settings using dapsone or rasburicase; recreational “poppers” or adulterated cocaine; and occupational/agricultural exposure to anilines, nitrobenzene, chlorates, pesticides, and nitrate-contaminated water. Tobacco, alcohol, exercise, and ordinary diet are not established independent causes, although smoking-related cardiorespiratory disease may reduce physiologic reserve. (belzer2024causesofacquired pages 2-3, iolascon2021recommendationsfordiagnosis pages 11-12)
Infections do not generally act as transmissible causes. Sepsis and infant gastroenteritis may increase endogenous nitric oxide/nitrite production or acidosis and thereby trigger MetHb formation. These are physiologic cofactors, not evidence of a pathogen-specific methemoglobinemia. (belzer2024causesofacquired pages 2-3, iolascon2021recommendationsfordiagnosis pages 8-9)
This is a redox/oxygen-transport disorder, not primarily a Wnt, MAPK, PI3K–AKT, mTOR, immune, apoptotic, or fibrotic disease. The initiating molecular lesion is oxidation within erythrocyte hemoglobin; downstream organ damage is hypoxic/ischemic. Suggested GO terms include oxidation–reduction process, oxygen binding, response to decreased oxygen levels, cellular response to hypoxia, and methemoglobin reductase activity. The principal Cell Ontology entity is erythrocyte CL:0000232. (belzer2024causesofacquired pages 1-2, mcnulty2022foodinducedmethemoglobinemiaa pages 1-1)
No reproducible disease-specific transcriptomic, proteomic, lipidomic, metabolomic, epigenomic, single-cell, spatial-transcriptomic, CRISPR-screen, or integrated multi-omics signature was identified. MetHb percentage itself is the direct biochemical phenotype.
The primary affected tissue is circulating blood, specifically hemoglobin in mature erythrocytes. The relevant subcellular context is erythrocyte cytosol and the heme prosthetic groups of hemoglobin; mature erythrocytes lack nuclei and mitochondria. Suggested terms include UBERON:0000178 blood, erythrocyte CL:0000232, hemoglobin complex, cytosol, and heme-binding site.
Secondary injury is systemic and proportional to oxygen demand: brain (confusion, seizure, coma), heart (angina, dysrhythmia, ischemia), skeletal muscle, kidney, and other organs may be affected by hypoxia. Lungs are not necessarily structurally diseased, explaining a normal PaO₂ despite cyanosis. There is no lateralization. (iolascon2021recommendationsfordiagnosis pages 3-5, cefalu2020methemoglobinemiainthe pages 1-3)
Onset is usually acute or subacute after exposure, with abrupt neurologic or cardiac symptoms distinguishing acquired disease from lifelong congenital cyanosis. Endogenous MetHb half-life has been estimated at approximately 55 minutes once oxidant input ceases. Effective methylene blue ordinarily lowers MetHb substantially within 30–60 minutes. (belzer2024causesofacquired pages 1-2, iolascon2021recommendationsfordiagnosis pages 9-10, iolascon2021recommendationsfordiagnosis pages 11-12)
The course is commonly self-limited after drug withdrawal, but dapsone can require treatment every 6–8 hours for 2–3 days. Rebound has been reported up to 18 hours after methylene blue, particularly with long-acting or lipophilic oxidants; one dapsone case fell from 25% to 7% and rebounded to 13.6% within six hours before a second dose. Serial co-oximetry is therefore important. (barclay2011dapsoneinducedmethemoglobinemiaa pages 5-6, iolascon2021recommendationsfordiagnosis pages 9-10, cefalu2020methemoglobinemiainthe pages 6-8)
Drug-induced methemoglobinemia is not inherited. Population prevalence and annual incidence are unknown because cases are sporadic, exposure-dependent, and under-recognized; no valid cases-per-100,000 estimate was found. There is no established sex ratio or ethnicity-specific incidence independent of exposure patterns and G6PD prevalence.
In the 2024 Iowa cohort, 303 unique patients had at least one result ≥3.1%, while only 27 had ≥10% during 2009–2023. Among ≥10% episodes across the longer dataset, causes included dapsone (40), benzocaine (10), recreational alkyl nitrites (3), sodium-nitrite suicide attempts (3, one fatal), nitrate-contaminated food (2), and sepsis (2). Severe intentional nitrite poisonings appear to be increasing with online availability, but this remains surveillance evidence rather than population incidence. (belzer2024causesofacquired pages 1-2, belzer2024causesofacquired pages 3-4, belzer2024causesofacquired pages 5-6)
Diagnosis rests on exposure history, cyanosis or hypoxia refractory to oxygen, an SpO₂–SaO₂ “saturation gap,” chocolate-brown blood, and multiwavelength co-oximetry. Conventional two-wavelength pulse oximeters cannot quantify MetHb and tend toward approximately 85%; PaO₂ measures dissolved oxygen and can remain normal or high. A saturation gap >5% is suggestive but not diagnostic. Arterial or venous blood co-oximetry directly reports MetHb as a percentage of total hemoglobin. (cefalu2020methemoglobinemiainthe pages 1-3, rathod2024shadesofblue pages 2-3, bai2024dapsoneinducedmethemoglobinemiain pages 3-4)
Additional tests should include CBC/hemoglobin, blood gas and lactate, renal/hepatic function where relevant, ECG for severe disease, and hemolysis studies—reticulocytes, bilirubin, LDH, haptoglobin, smear/Heinz bodies—when dapsone, rasburicase, sulfonamides, or G6PD deficiency are plausible. Imaging, biopsy, EEG, and pulmonary-function testing are not diagnostic unless needed to evaluate competing pathology.
Differentials include cardiopulmonary hypoxemia/right-to-left shunt, carboxyhemoglobinemia, sulfhemoglobinemia, cyanide toxicity, peripheral vasoconstriction/artifact, congenital CYB5R3 deficiency, HbM, and unstable hemoglobin. Sulfhemoglobin is not reducible by methylene blue and can interfere with some measurements. Persistent lifelong/familial cyanosis favors hereditary disease. (iolascon2021recommendationsfordiagnosis pages 5-6, gehle2013atsdrcasestudies pages 81-87, bai2024dapsoneinducedmethemoglobinemiain pages 3-4)
There is no general-population or newborn screening program for the acquired disease. Targeted surveillance is used during dapsone and inhaled-NO treatment and in high-risk anesthesia settings. A completed prospective liposuction study followed 133 patients over 24 hours, and a pediatric dental study randomized 91 children to prilocaine, lidocaine, or no local anesthetic with continuous pulse co-oximetry. (NCT01766999 chunk 1, NCT01402869 chunk 1)
Promptly recognized disease generally resolves completely without chronic disability. A 2024 five-patient series reported peak MetHb of 16.6%–41%; four received methylene blue and all recovered. (rathod2024shadesofblue pages 3-5, rathod2024shadesofblue pages 2-3)
Risk rises sharply at 50%–70%, and >70% is potentially fatal, but level alone is imperfect because rate of rise, anemia, and cardiopulmonary reserve matter. In the food/nitrate systematic review, 97 articles described 568 cases, median MetHb 30%; 35 deaths occurred, 32 after accidental ingestion. Most patients survived even at levels up to 89% when methylene blue was administered, and methylene blue alone produced a mean 39.1-percentage-point fall among 22 evaluable cases. These data concern acquired food/nitrite poisoning and are supportive rather than drug-specific efficacy estimates. (mcnulty2022foodinducedmethemoglobinemiaa pages 1-1)
The Iowa cohort found no therapeutic-dose dapsone-attributed fatalities, whereas one of three sodium-nitrite suicide attempts was fatal. Death recorded during an encounter often reflected severe underlying illness rather than MetHb itself. No 5- or 10-year survival metric, chronic disability index, EQ-5D, SF-36, or validated prognostic model is applicable. (belzer2024causesofacquired pages 4-5, belzer2024causesofacquired pages 5-6)
There is no role for surgery, gene therapy, cell therapy, RNA therapy, or immunotherapy. Completed real-world implementation studies include the 24-person acquired-MetHb registry NCT03542760 and the seven-person open-label Phase 4 ProvayBlue study NCT03395223, which used 1 mg/kg IV and permitted one repeat dose after an hour. Small enrollment underscores the rarity and limited prospective evidence base. (NCT03542760 chunk 1, NCT03395223 chunk 1)
Primary prevention: maintain electronic medication alerts; avoid benzocaine/prilocaine or excessive doses in susceptible patients; calculate weight-based local-anesthetic exposure; review concurrent oxidants; use safer PCP-prophylaxis alternatives when appropriate; prevent nitrate/nitrite ingestion; regulate access and clearly label sodium nitrite; and use occupational controls/PPE for anilines and pesticides. (belzer2024causesofacquired pages 2-3, iolascon2021recommendationsfordiagnosis pages 11-12)
Secondary prevention: recognize the saturation gap early, obtain co-oximetry, and monitor MetHb during dapsone, inhaled nitric oxide, nitroprusside, and high-risk anesthesia. Routine dapsone monitoring in the Iowa center detected many asymptomatic cases and allowed dose reduction or discontinuation; only three dapsone patients required methylene blue. (belzer2024causesofacquired pages 3-4, belzer2024causesofacquired pages 5-6)
Tertiary prevention: document the culprit as a serious adverse drug reaction, avoid re-exposure, monitor for rebound for at least the expected pharmacologic window, and assess hemolysis where relevant. Vaccination and antimicrobial prophylaxis do not prevent the dyshemoglobinemia itself. Genetic counseling is unnecessary for an isolated acquired episode, but is appropriate if persistent/familial findings suggest hereditary disease.
The conserved vertebrate mechanism—heme Fe²⁺ oxidation to Fe³⁺—occurs in mammals and birds. Veterinary cases can follow acetaminophen, local anesthetics, nitrates/nitrites, PAPP bait, and other oxidants; cats and dogs are especially relevant non-target species. This is not infectious and has no zoonotic transmission.
An in-vitro comparative study used blood from coyote (Canis latrans), California vole (Microtus californicus), feral swine (Sus scrofa), European starling (Sturnus vulgaris), and mallard (Anas platyrhynchos). Mammalian blood reached 100% MetHb at 15 mM sodium nitrite versus 200 mM for avian blood, while color values at a given MetHb fraction were similar enough to support a cross-species blood-spot diagnostic card. (patton2016detectingmethemoglobinemiain pages 1-2)
Acetaminophen studies indicate metabolic activation to p-aminophenol is important: at 500 µM p-aminophenol, canine and feline erythrocytes generated more MetHb than rat or mouse cells, plausibly reflecting lower NADH-methemoglobin-reductase and N-acetyltransferase detoxification. This makes species extrapolation imperfect. (mcconkey2007themechanismof pages 132-137)
Available models are chiefly induced toxicology models, not genetic replicas of the heterogeneous human exposure syndrome:
Suggested resources are MGI, RGD, ZFIN, OMIA, and NCBI Taxonomy. No standardized knockout, organoid, iPSC, or humanized model is required to diagnose or treat the acquired disease.
The most consequential 2023–2024 development is improved quantitative description of real-world causes: the March/June 2024 Iowa study shows dapsone and iatrogenic nitric oxide dominate mild monitored cases, while intentional nitrite exposure and historical benzocaine use disproportionately contribute to severe episodes. It also documents institutional reduction in benzocaine-associated severe disease, consistent with prevention through changed procedural practice. (belzer2024causesofacquired pages 1-2, belzer2024causesofacquired pages 5-6)
Prospective evidence remains sparse. The FDA-requested Phase 4 study enrolled only seven patients, and the multicenter registry enrolled 24. Thus, expert recommendations appropriately rely on mechanism, observational cohorts, case series, and long clinical experience rather than randomized antidote trials. (NCT03542760 chunk 1, NCT03395223 chunk 1)
https://pubmed.ncbi.nlm.nih.gov/<PMID>/. (NCT01402869 chunk 1, NCT01402869 chunk 2)Knowledge gaps: no reliable population prevalence/incidence, validated patient-reported outcome instrument, disease-specific omics signature, GWAS architecture, or adequately powered randomized antidote trial is available. Exact ontology identifiers for a dedicated drug-induced MONDO/ICD-11 subtype should be terminology-validated before database release.
References
(iolascon2021recommendationsfordiagnosis pages 1-3): Achille Iolascon, Paola Bianchi, Immacolata Andolfo, Roberta Russo, Wilma Barcellini, Elisa Fermo, Gergely Toldi, Stefano Ghirardello, David Rees, Richard Van Wijk, Antonis Kattamis, Patrick G. Gallagher, Noemi Roy, Ali Taher, Razan Mohty, Andreas Kulozik, Lucia De Franceschi, Antonella Gambale, Mariane De Montalembert, Gian Luca Forni, Cornelis L. Harteveld, and Josef Prchal. Recommendations for diagnosis and treatment of methemoglobinemia. Sep 2021. URL: https://doi.org/10.1002/ajh.26340, doi:10.1002/ajh.26340. This article has 319 citations and is from a domain leading peer-reviewed journal.
(belzer2024causesofacquired pages 1-2): Alex Belzer and Matthew D. Krasowski. Causes of acquired methemoglobinemia – a retrospective study at a large academic hospital. Jun 2024. URL: https://doi.org/10.1016/j.toxrep.2024.03.004, doi:10.1016/j.toxrep.2024.03.004. This article has 38 citations and is from a peer-reviewed journal.
(iolascon2021recommendationsfordiagnosis pages 9-10): Achille Iolascon, Paola Bianchi, Immacolata Andolfo, Roberta Russo, Wilma Barcellini, Elisa Fermo, Gergely Toldi, Stefano Ghirardello, David Rees, Richard Van Wijk, Antonis Kattamis, Patrick G. Gallagher, Noemi Roy, Ali Taher, Razan Mohty, Andreas Kulozik, Lucia De Franceschi, Antonella Gambale, Mariane De Montalembert, Gian Luca Forni, Cornelis L. Harteveld, and Josef Prchal. Recommendations for diagnosis and treatment of methemoglobinemia. Sep 2021. URL: https://doi.org/10.1002/ajh.26340, doi:10.1002/ajh.26340. This article has 319 citations and is from a domain leading peer-reviewed journal.
(belzer2024causesofacquired pages 3-4): Alex Belzer and Matthew D. Krasowski. Causes of acquired methemoglobinemia – a retrospective study at a large academic hospital. Jun 2024. URL: https://doi.org/10.1016/j.toxrep.2024.03.004, doi:10.1016/j.toxrep.2024.03.004. This article has 38 citations and is from a peer-reviewed journal.
(belzer2024causesofacquired pages 2-3): Alex Belzer and Matthew D. Krasowski. Causes of acquired methemoglobinemia – a retrospective study at a large academic hospital. Jun 2024. URL: https://doi.org/10.1016/j.toxrep.2024.03.004, doi:10.1016/j.toxrep.2024.03.004. This article has 38 citations and is from a peer-reviewed journal.
(iolascon2021recommendationsfordiagnosis pages 3-5): Achille Iolascon, Paola Bianchi, Immacolata Andolfo, Roberta Russo, Wilma Barcellini, Elisa Fermo, Gergely Toldi, Stefano Ghirardello, David Rees, Richard Van Wijk, Antonis Kattamis, Patrick G. Gallagher, Noemi Roy, Ali Taher, Razan Mohty, Andreas Kulozik, Lucia De Franceschi, Antonella Gambale, Mariane De Montalembert, Gian Luca Forni, Cornelis L. Harteveld, and Josef Prchal. Recommendations for diagnosis and treatment of methemoglobinemia. Sep 2021. URL: https://doi.org/10.1002/ajh.26340, doi:10.1002/ajh.26340. This article has 319 citations and is from a domain leading peer-reviewed journal.
(iolascon2021recommendationsfordiagnosis pages 10-11): Achille Iolascon, Paola Bianchi, Immacolata Andolfo, Roberta Russo, Wilma Barcellini, Elisa Fermo, Gergely Toldi, Stefano Ghirardello, David Rees, Richard Van Wijk, Antonis Kattamis, Patrick G. Gallagher, Noemi Roy, Ali Taher, Razan Mohty, Andreas Kulozik, Lucia De Franceschi, Antonella Gambale, Mariane De Montalembert, Gian Luca Forni, Cornelis L. Harteveld, and Josef Prchal. Recommendations for diagnosis and treatment of methemoglobinemia. Sep 2021. URL: https://doi.org/10.1002/ajh.26340, doi:10.1002/ajh.26340. This article has 319 citations and is from a domain leading peer-reviewed journal.
(iolascon2021recommendationsfordiagnosis pages 8-9): Achille Iolascon, Paola Bianchi, Immacolata Andolfo, Roberta Russo, Wilma Barcellini, Elisa Fermo, Gergely Toldi, Stefano Ghirardello, David Rees, Richard Van Wijk, Antonis Kattamis, Patrick G. Gallagher, Noemi Roy, Ali Taher, Razan Mohty, Andreas Kulozik, Lucia De Franceschi, Antonella Gambale, Mariane De Montalembert, Gian Luca Forni, Cornelis L. Harteveld, and Josef Prchal. Recommendations for diagnosis and treatment of methemoglobinemia. Sep 2021. URL: https://doi.org/10.1002/ajh.26340, doi:10.1002/ajh.26340. This article has 319 citations and is from a domain leading peer-reviewed journal.
(cefalu2020methemoglobinemiainthe pages 6-8): John N. Cefalu, Tejas V. Joshi, Matthew J. Spalitta, Carson J. Kadi, James H. Diaz, Jonathan P. Eskander, Elyse M. Cornett, and Alan D. Kaye. Methemoglobinemia in the operating room and intensive care unit: early recognition, pathophysiology, and management. Advances in Therapy, 37:1714-1723, Mar 2020. URL: https://doi.org/10.1007/s12325-020-01282-5, doi:10.1007/s12325-020-01282-5. This article has 104 citations and is from a peer-reviewed journal.
(iolascon2021recommendationsfordiagnosis pages 5-6): Achille Iolascon, Paola Bianchi, Immacolata Andolfo, Roberta Russo, Wilma Barcellini, Elisa Fermo, Gergely Toldi, Stefano Ghirardello, David Rees, Richard Van Wijk, Antonis Kattamis, Patrick G. Gallagher, Noemi Roy, Ali Taher, Razan Mohty, Andreas Kulozik, Lucia De Franceschi, Antonella Gambale, Mariane De Montalembert, Gian Luca Forni, Cornelis L. Harteveld, and Josef Prchal. Recommendations for diagnosis and treatment of methemoglobinemia. Sep 2021. URL: https://doi.org/10.1002/ajh.26340, doi:10.1002/ajh.26340. This article has 319 citations and is from a domain leading peer-reviewed journal.
(NCT03542760 chunk 2): Acquired Methemoglobinemia Observational Registry. Hospital Quality Foundation. 2018. ClinicalTrials.gov Identifier: NCT03542760
(cefalu2020methemoglobinemiainthe pages 4-6): John N. Cefalu, Tejas V. Joshi, Matthew J. Spalitta, Carson J. Kadi, James H. Diaz, Jonathan P. Eskander, Elyse M. Cornett, and Alan D. Kaye. Methemoglobinemia in the operating room and intensive care unit: early recognition, pathophysiology, and management. Advances in Therapy, 37:1714-1723, Mar 2020. URL: https://doi.org/10.1007/s12325-020-01282-5, doi:10.1007/s12325-020-01282-5. This article has 104 citations and is from a peer-reviewed journal.
(iolascon2021recommendationsfordiagnosis pages 11-12): Achille Iolascon, Paola Bianchi, Immacolata Andolfo, Roberta Russo, Wilma Barcellini, Elisa Fermo, Gergely Toldi, Stefano Ghirardello, David Rees, Richard Van Wijk, Antonis Kattamis, Patrick G. Gallagher, Noemi Roy, Ali Taher, Razan Mohty, Andreas Kulozik, Lucia De Franceschi, Antonella Gambale, Mariane De Montalembert, Gian Luca Forni, Cornelis L. Harteveld, and Josef Prchal. Recommendations for diagnosis and treatment of methemoglobinemia. Sep 2021. URL: https://doi.org/10.1002/ajh.26340, doi:10.1002/ajh.26340. This article has 319 citations and is from a domain leading peer-reviewed journal.
(cefalu2020methemoglobinemiainthe pages 8-10): John N. Cefalu, Tejas V. Joshi, Matthew J. Spalitta, Carson J. Kadi, James H. Diaz, Jonathan P. Eskander, Elyse M. Cornett, and Alan D. Kaye. Methemoglobinemia in the operating room and intensive care unit: early recognition, pathophysiology, and management. Advances in Therapy, 37:1714-1723, Mar 2020. URL: https://doi.org/10.1007/s12325-020-01282-5, doi:10.1007/s12325-020-01282-5. This article has 104 citations and is from a peer-reviewed journal.
(bai2024dapsoneinducedmethemoglobinemiain pages 3-4): Sakshi Bai, Abraham Kisule, Bipneet Singh, Kavita Luthra, and Danesh Kumar. Dapsone-induced methemoglobinemia in a woman with multiple myeloma without glucose-6-phosphate dehydrogenase (g6pd) deficiency. Jun 2024. URL: https://doi.org/10.7759/cureus.63249, doi:10.7759/cureus.63249. This article has 3 citations.
(barclay2011dapsoneinducedmethemoglobinemiaa pages 5-5): James A Barclay, Stamatina E Ziemba, and Rami B Ibrahim. Dapsone-induced methemoglobinemia: a primer for clinicians. Annals of Pharmacotherapy, 45:1103-1115, Sep 2011. URL: https://doi.org/10.1345/aph.1q139, doi:10.1345/aph.1q139. This article has 101 citations and is from a peer-reviewed journal.
(cefalu2020methemoglobinemiainthe pages 3-4): John N. Cefalu, Tejas V. Joshi, Matthew J. Spalitta, Carson J. Kadi, James H. Diaz, Jonathan P. Eskander, Elyse M. Cornett, and Alan D. Kaye. Methemoglobinemia in the operating room and intensive care unit: early recognition, pathophysiology, and management. Advances in Therapy, 37:1714-1723, Mar 2020. URL: https://doi.org/10.1007/s12325-020-01282-5, doi:10.1007/s12325-020-01282-5. This article has 104 citations and is from a peer-reviewed journal.
(belzer2024causesofacquired pages 4-5): Alex Belzer and Matthew D. Krasowski. Causes of acquired methemoglobinemia – a retrospective study at a large academic hospital. Jun 2024. URL: https://doi.org/10.1016/j.toxrep.2024.03.004, doi:10.1016/j.toxrep.2024.03.004. This article has 38 citations and is from a peer-reviewed journal.
(mcnulty2022foodinducedmethemoglobinemiaa pages 1-1): Richard McNulty, Nikhil Kuchi, Elena Xu, and Naren Gunja. Food-induced methemoglobinemia: a systematic review. Journal of food science, 87 4:1423-1448, Mar 2022. URL: https://doi.org/10.1111/1750-3841.16090, doi:10.1111/1750-3841.16090. This article has 64 citations and is from a peer-reviewed journal.
(cefalu2020methemoglobinemiainthe pages 1-3): John N. Cefalu, Tejas V. Joshi, Matthew J. Spalitta, Carson J. Kadi, James H. Diaz, Jonathan P. Eskander, Elyse M. Cornett, and Alan D. Kaye. Methemoglobinemia in the operating room and intensive care unit: early recognition, pathophysiology, and management. Advances in Therapy, 37:1714-1723, Mar 2020. URL: https://doi.org/10.1007/s12325-020-01282-5, doi:10.1007/s12325-020-01282-5. This article has 104 citations and is from a peer-reviewed journal.
(barclay2011dapsoneinducedmethemoglobinemiaa pages 5-6): James A Barclay, Stamatina E Ziemba, and Rami B Ibrahim. Dapsone-induced methemoglobinemia: a primer for clinicians. Annals of Pharmacotherapy, 45:1103-1115, Sep 2011. URL: https://doi.org/10.1345/aph.1q139, doi:10.1345/aph.1q139. This article has 101 citations and is from a peer-reviewed journal.
(belzer2024causesofacquired pages 5-6): Alex Belzer and Matthew D. Krasowski. Causes of acquired methemoglobinemia – a retrospective study at a large academic hospital. Jun 2024. URL: https://doi.org/10.1016/j.toxrep.2024.03.004, doi:10.1016/j.toxrep.2024.03.004. This article has 38 citations and is from a peer-reviewed journal.
(rathod2024shadesofblue pages 2-3): Bharatsing D Rathod, Nilesh Kamble, Onkar Awadhiya, Udit Narang, Rajashree S Khot, and Sunita Kumbhalkar. Shades of blue: a case series of acquired methemoglobinemia. Apr 2024. URL: https://doi.org/10.7759/cureus.58312, doi:10.7759/cureus.58312. This article has 3 citations.
(gehle2013atsdrcasestudies pages 81-87): K Gehle. Atsdr case studies in environmental medicine: nitrate/nitrite toxicity. Unknown journal, 2013.
(NCT01766999 chunk 1): Hartmut Gehring. Methemoglobinemia After Liposuction - Diagnostic by Pulse Oximetry and Blood Gas Analysis.. University Hospital Schleswig-Holstein. 2008. ClinicalTrials.gov Identifier: NCT01766999
(NCT01402869 chunk 1): Lauren GutenBerg. Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Local Anesthetics. Loma Linda University. 2011. ClinicalTrials.gov Identifier: NCT01402869
(rathod2024shadesofblue pages 3-5): Bharatsing D Rathod, Nilesh Kamble, Onkar Awadhiya, Udit Narang, Rajashree S Khot, and Sunita Kumbhalkar. Shades of blue: a case series of acquired methemoglobinemia. Apr 2024. URL: https://doi.org/10.7759/cureus.58312, doi:10.7759/cureus.58312. This article has 3 citations.
(mcnulty2022foodinducedmethemoglobinemiaa pages 3-3): Richard McNulty, Nikhil Kuchi, Elena Xu, and Naren Gunja. Food-induced methemoglobinemia: a systematic review. Journal of food science, 87 4:1423-1448, Mar 2022. URL: https://doi.org/10.1111/1750-3841.16090, doi:10.1111/1750-3841.16090. This article has 64 citations and is from a peer-reviewed journal.
(NCT03542760 chunk 1): Acquired Methemoglobinemia Observational Registry. Hospital Quality Foundation. 2018. ClinicalTrials.gov Identifier: NCT03542760
(NCT03395223 chunk 1): MEthylene Blue In Patients With Acquired Methemoglobinemia. Provepharm SAS. 2018. ClinicalTrials.gov Identifier: NCT03395223
(patton2016detectingmethemoglobinemiain pages 1-2): Toni G. Patton, Stephen L. Blamer, and Katherine E. Horak. Detecting methemoglobinemia in animals with a drop of blood. PLoS ONE, 11:e0167942, Dec 2016. URL: https://doi.org/10.1371/journal.pone.0167942, doi:10.1371/journal.pone.0167942. This article has 17 citations and is from a peer-reviewed journal.
(mcconkey2007themechanismof pages 132-137): SE McConkey. The mechanism of acetaminophen-induced methemoglobinemia in dogs and cats. Unknown journal, 2007.
(miller2021safetyandtoxicology pages 1-2): Lutfiya Miller, Charles D. Hébert, Sheila D. Grimes, James S. Toomey, Joo-Yeun Oh, Jason J. Rose, and Rakesh P. Patel. Safety and toxicology assessment of sodium nitrite administered by intramuscular injection. Oct 2021. URL: https://doi.org/10.1016/j.taap.2021.115702, doi:10.1016/j.taap.2021.115702. This article has 2 citations and is from a highest quality peer-reviewed journal.
(NCT01402869 chunk 2): Lauren GutenBerg. Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Local Anesthetics. Loma Linda University. 2011. ClinicalTrials.gov Identifier: NCT01402869
Checked with linkml-reference-validator 0.2.1.
| Outcome | Count |
|---|---|
| References checked | 14 |
| Resolved | 14 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 14 |
| On topic | 4 |
| Off topic | 0 |
All extracted references resolved successfully.